Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Durvalumab Plus Chemotherapy in MP2 HR+/HER2- Stage II-III Breast Cancer
NCT06058377Phase 3Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2023
- Primary completion
- May 2032
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of durvalumab in breast cancer (2 arms), sponsored by National Cancer Institute. Primary endpoints: Breast cancer event-free survival at 10 years, Patient Reported Outcomes Measurement Information System Fatigue at 2 years and 1 more. Started Nov 2023; status: recruiting.
02
Drugs
durvalumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06058377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058377.